Education
About Us
Working with TipRanks
Follow Us
Bolt Biotherapeutics (BOLT)
NASDAQ:BOLT
BOLT Stock Chart & Stats
$6.71
-$0.02(-3.16%)
At close: 4:00 PM EST
$6.71
-$0.02(-3.16%)
Day’s Range― - ―
52-Week Range$4.41 - $10.52
Previous CloseN/A
Volume72.19K
Average Volume (3M)29.18K
Market Cap
$12.88M
Enterprise Value$17.83M
Total Cash (Recent Filing)$31.91M
Total Debt (Recent Filing)$23.59M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Apr 01, 2026EPS Estimate
-6.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.72
Shares Outstanding1,919,441
10 Day Avg. Volume31,146
30 Day Avg. Volume29,181
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)7.14
Price to Sales (P/S)53.13
P/FCF Ratio-6.66
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue3.43
Enterprise Value/Gross Profit3.98
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$41.00Price Target Upside511.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Comparative EfficacyEarly data indicate BDC-4182 delivered stronger anti-tumor activity than cytotoxic Claudin-18.2 ADCs and retained efficacy in low-antigen-density models, supporting potential advantage in difficult-to-treat tumors.
Financial PositionA narrower-than-expected net loss alongside a cash position that supports operations into 2027 reduces near-term financing pressure and provides runway to advance clinical programs.
Mechanism Of ActionBDC-4182 employs a toll-like receptor 7/8 immune-stimulatory payload rather than a cytotoxic warhead, offering a differentiated approach that could trigger broader anti-tumor immune responses compared with conventional ADCs.
Bears Say
Clinical Timeline And Dosing UncertaintyA dosing change to step-up regimens driven by strong immune responses at initial dose levels introduces uncertainty around the timing and interpretation of forthcoming BDC-4182 data releases.
Operational CapacityA reduction of about half the workforce could strain trial execution and program support, potentially slowing key development milestones despite extending cash runway.
Regulatory And Market RiskExposure to potential negative efficacy readouts, stronger competitor data, FDA non-approval and possible dilution contributes to low Street expectations and pressures enterprise valuation.
Bolt Biotherapeutics News
BOLT FAQ
What was Bolt Biotherapeutics’s price range in the past 12 months?
Bolt Biotherapeutics lowest stock price was $4.41 and its highest was $10.52 in the past 12 months.
What is Bolt Biotherapeutics’s market cap?
Bolt Biotherapeutics’s market cap is $12.88M.
When is Bolt Biotherapeutics’s upcoming earnings report date?
Bolt Biotherapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 61 days.
How were Bolt Biotherapeutics’s earnings last quarter?
Bolt Biotherapeutics released its earnings results on Nov 12, 2025. The company reported -$3.72 earnings per share for the quarter, beating the consensus estimate of -$5.676 by $1.956.
Is Bolt Biotherapeutics overvalued?
According to Wall Street analysts Bolt Biotherapeutics’s price is currently Undervalued.
Does Bolt Biotherapeutics pay dividends?
Bolt Biotherapeutics pays a Quarterly dividend of $0.09 which represents an annual dividend yield of N/A. See more information on Bolt Biotherapeutics dividends here
What is Bolt Biotherapeutics’s EPS estimate?
Bolt Biotherapeutics’s EPS estimate is -6.11.
How many shares outstanding does Bolt Biotherapeutics have?
Bolt Biotherapeutics has 1,919,441 shares outstanding.
What happened to Bolt Biotherapeutics’s price movement after its last earnings report?
Bolt Biotherapeutics reported an EPS of -$3.72 in its last earnings report, beating expectations of -$5.676. Following the earnings report the stock price went down -2.495%.
Which hedge fund is a major shareholder of Bolt Biotherapeutics?
Currently, no hedge funds are holding shares in BOLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
BOLT Stock 12 Month Forecast
Average Price Target
$41.00
▲(511.03% Upside)
Technical Analysis
Ownership Overview
5.54% Insiders
5.10% Mutual Funds
35.32% Other Institutional Investors
53.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---